Alternative approaches to retroperitoneal lymph node dissection for paratesticular rhabdomyosarcoma

Space: StayCurrentMD Author: Sara A. Mansfield, Andrew J. Murphy, Lindsay Talbot, Hasmukh Prajapati, Vinod Maller, Alberto Pappo, Sunil Singhal, Matthew J. Krasin, Andrew M. Davidoff, Abdelhafeez Abdelhafeez Published:

Author / Expert

Sara A. Mansfield, Andrew J. Murphy, Lindsay Talbot, Hasmukh Prajapati, Vinod Maller, Alberto Pappo, Sunil Singhal, Matthew J. Krasin, Andrew M. Davidoff, Abdelhafeez Abdelhafeez

Topic overview

Abstract

Purpose

The aim of this study was to evaluate outcomes based on surgical approach for retroperitoneal lymph node dissection (RPLND) in patients with paratesticular rhabdomyosarcoma (PT-RMS).

Methods

Patients undergoing RPLND for PT-RMS over 10 years at a single institution were retrospectively reviewed. Length of stay (LOS), complications, oral morphine equivalents per kilogram (OME/Kg), lymph node yield, and time to chemotherapy were assessed. The surgical approaches compared were: open transabdominal, open extraperitoneal, laparoscopic, and retroperitoneoscopic. For cases with lymphatic mapping, indocyanine green (ICG) was injected into the spermatic cord.

Results

Twenty patients were included: five open transabdominal, six open extraperitoneal, three laparoscopic, and six retroperitoneoscopic operations. LOS was shorter in the retroperitoneoscopic group than laparoscopic (p = 0.029) and both open groups (p < 0.001). Mean OME/kg used was lowest in the retroperitoneoscopic (0.13 ± 0.15) group compared to laparoscopic (0.68 ± 0.53, p = 0.043), open transabdominal (14.90 ± 8.87, p = 0.003), and extraperitoneal (10.11 ± 2.44, p < 0.001). Time to chemotherapy was shorter for retroperitoneoscopic patients (0.13 days ± 0.15) compared to open transabdominal (15.6 days±6.5, p = 0.005). There was no difference in lymph node yield between groups. Spermatic cord ICG demonstrated iliac lymph node avidity on near-infrared spectroscopy.

Conclusions

Minimally invasive RPLND appears to offer a faster recovery without compromising lymph node yield for patients with PT-RMS.

Level of Evidence

III.

Keywords

Hashtags

0 Views
0 Comments

Comments

Loading comments...